Skip to main content
. 2021 May 22;13(6):778. doi: 10.3390/pharmaceutics13060778

Figure 7.

Figure 7

Cabozantinib plasma concentration time profiles in linear (A) and semi-logarithmic (B) representation after a single oral dose of 140 mg Cabozantinib (capsule formulation) without and with rifampin co-administration. Observed data are shown as dots. Population simulation (n = 100) geometric means are shown as lines; the shaded areas represent the predicted population geometric SD.